Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world naxitamab in high-risk neuroblastoma (Fudan single-center observational study)
ChiCTR2500095479Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of naxitamab in neuroblastoma (3 cohorts), sponsored by Children's Hospital of Fudan University. Primary endpoint: 2-year event-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on ChiCTR2500095479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095479.